ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.

FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...

Natco Pharma and Lupin gained FDA approval for bioequivalent generic eribulin mesylate injection, potentially reducing ...

Fast track status enables more frequent FDA interactions and may support priority review or accelerated approval pathways if predefined clinical criteria are met. Selective AKT1 targeting is intended ...

CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

Michael C. Heinrich, MD, discusses the eventual goal of using velzatinib as an early-line treatment for gastrointestinal stromal tumors. Michael C. Heinrich, MD, of Oregon Health and Science ...

ASCO 2026 insights on 177Lu-PSMA-617 in mHSPC: safety, marrow and kidney monitoring, and what long-term MDS/AML risks may ...

Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...

Daraxonrasib reduced mortality risk versus chemotherapy in previously treated RAS G12–mutant mPDAC (OS HR 0.40) with fewer discontinuations and delayed pain/QoL deterioration. Perioperative ...

FDA priority review positions giredestrant as a potential first oral SERD to demonstrate statistically significant benefit in the curative early-stage ER-positive, HER2-negative setting. lidERA ...

Survival outcomes were favorable post-ASCT, with 90% 1- and 2-year OS, 82% 1-year EFS, and low nonrelapse mortality (4%), in a cohort enriched for KMT2Ar AML. Landmark comparisons suggested reduced ...

PFS2 improved with sacituzumab govitecan/pembrolizumab: median not reached vs 21.0 months; HR 0.67 (33% risk reduction) for progression on next therapy or death. Control-arm crossover was extensive, ...